TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18718094

Group type: EXPERIMENTAL
Intervention: Rituximab plus CHOP (R-CHOP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: CHOP alone (CHOP group)
Number of subjects: 69
Study: 16685985

Group type: EXPERIMENTAL
Intervention: 4D statistical atlas of cardiac anatomy
Number of subjects: 26
Study: 12807526

Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan (E40)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: 80 mg eletriptan (E80)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study: 10806014

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 731

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Exercise testing results
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Anginal pain
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Short-term treatment effects on ischaemia
Number of subjects: 731
Study: 8969978

Group type: EXPERIMENTAL
Intervention: Pretreatment with erythropoietin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1672389

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination of children aged between 0 and 4 years
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination of children between 1 and 9 months old
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination regimens
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Vaccination against HBV
Number of subjects: 358
Study: 6141797

Group type: EXPERIMENTAL
Intervention: Test preparation (Normoc)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard preparation (commercially available)
Number of subjects: 10
Study: 31371164

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation combined with music for 20 minutes, for a total of eight weeks in group sessions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Attention-matched education (control group) for 20 minutes
Number of subjects: 56
Study: 28826313

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1,200 mg daily for 8 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (paraffin)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Omega-3 supplementation and Placebo
Number of subjects: 42
Study: 26208048

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg per day for the first week, followed by 40 mg per day from weeks 2 through 12
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 23841970

Group type: EXPERIMENTAL
Intervention: Horseback riding therapy (HBRT) plus conventional physiotherapy for 16 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional physiotherapy (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Horseback riding therapy (HBRT) plus conventional physiotherapy
Number of subjects: 24
Study: 21350878

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 68

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 68
Study: 19346285

Group type: EXPERIMENTAL
Intervention: Adjusted indirect comparison using classic frequentist methods (n=49)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Adjusted indirect comparison using more complex methods (n=18)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Informal indirect comparison
Number of subjects: 88

Group type: COMPARATOR
Intervention: Naive comparison without common control
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Head to head comparison trials
Number of subjects: 88
Study: 17649636

Group type: EXPERIMENTAL
Intervention: h-R3 plus radiotherapy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 137
Study: 15506603

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 1068
Study: 11735640

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9156142

Group type: EXPERIMENTAL
Intervention: Rapid detection of pneumococcal antigen by latex agglutination
Number of subjects: 110
Study: 7525661

Group type: EXPERIMENTAL
Intervention: Intravenous FK506 (20 micrograms/kg x 4 hours)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral FK506 (80 micrograms/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 6
Study: 3310632

Group type: EXPERIMENTAL
Intervention: 1 g four times daily (group A, n = 131)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 2 g twice daily (group B, n = 128)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 1 g four times daily (group A)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 2 g twice daily (group B)
Number of subjects: 222
Study: 31132095

Group type: EXPERIMENTAL
Intervention: Black text on white background (BW)
Number of subjects: 1854

Group type: EXPERIMENTAL
Intervention: Black on yellow (BY)
Number of subjects: 1854

Group type: EXPERIMENTAL
Intervention: Novel shape
Number of subjects: 1854

Group type: EXPERIMENTAL
Intervention: Signal word present
Number of subjects: 1854

Group type: COMPARATOR
Intervention: Shape and signal word
Number of subjects: 1854
Study: 29043600

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine hydrochloride SGB
Number of subjects: 96

Group type: COMPARATOR
Intervention: Saline SGB
Number of subjects: 96
Study: 27187435

Group type: EXPERIMENTAL
Intervention: Brazilian green propolis (900 mg/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 25887113

Group type: EXPERIMENTAL
Intervention: TriAtiva Program: Education, Nutrition and Physical Activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (six schools)
Number of subjects: 0
Study: 23415048

Group type: EXPERIMENTAL
Intervention: Real-time MRI-guided interstitial brachytherapy
Number of subjects: 25
Study: 20609003

Group type: EXPERIMENTAL
Intervention: VAAM ingestion (3000 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18726947

Group type: EXPERIMENTAL
Intervention: 0.2 mg of oral desmopressin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17680819

Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15007359

Group type: EXPERIMENTAL
Intervention: DBPCFC (Double-Blind, Placebo-Controlled Food Challenge)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DBPCFC
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IgE immunoblotting
Number of subjects: 43
Study: 11520009

Group type: EXPERIMENTAL
Intervention: Suppression (n=21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-suppression (n=19)
Number of subjects: 40
Study: 10192125

Group type: EXPERIMENTAL
Intervention: Lidocaine 2 per cent plus bicarbonate 8.4 per cent
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine 2 per cent alone
Number of subjects: 60
Study: 8739022

Group type: EXPERIMENTAL
Intervention: CGP 36,742 (600 mg single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2127791

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2a (6 million units thrice weekly for 1 month, followed by 3 million units for 3 months, and 1 million units maintenance therapy for 8 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of patients' sera for antibody to hepatitis C virus
Number of subjects: 60
Study: 6996123

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucralfate (for large ulcers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (for large ulcers)
Number of subjects: 0
Study: 31581898

Group type: EXPERIMENTAL
Intervention: Handgrip exercise for 8 weeks
Number of subjects: 34
Study: 30629984

Group type: EXPERIMENTAL
Intervention: Self-controlled group (controlling difficulty for each block in a videogame task)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Yoked group (difficulty matched to a self-controlled counterpart)
Number of subjects: 60
Study: 28062937

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 148
Study: 25533997

Group type: EXPERIMENTAL
Intervention: Fluoxetine (single dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25311949

Group type: EXPERIMENTAL
Intervention: C‐MAC® videolaryngoscope
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: McGrath® videolaryngoscope
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: GlideScope® Cobalt videolaryngoscope
Number of subjects: 141

Group type: COMPARATOR
Intervention: Classic Macintosh MAC 3 laryngoscope
Number of subjects: 141
Study: 23289490

Group type: EXPERIMENTAL
Intervention: Positive social norms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative social norms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injunctive norms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive norms
Number of subjects: 0
Study: 21479856

Group type: EXPERIMENTAL
Intervention: CEUS with 0.12 μL/kg perfluorobutane microbubbles
Number of subjects: 157

Group type: COMPARATOR
Intervention: US
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: CEUS (all doses combined)
Number of subjects: 157
Study: 18467147

Group type: EXPERIMENTAL
Intervention: Skin infiltration with 20 ml of ropivacaine 0.75% (Gr R)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Skin infiltration with 20 ml of 0.9% saline solution (Gr P)
Number of subjects: 42
Study: 16204359

Group type: EXPERIMENTAL
Intervention: Theophylline (1 mg/kg IV for three days)
Number of subjects: 50
Study: 12704366

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11113831

Group type: EXPERIMENTAL
Intervention: Test group (N = 145) with multivariate analyses to elaborate the PRAM
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Validation group (N = 72)
Number of subjects: 217
Study: 9761805

Group type: EXPERIMENTAL
Intervention: Flutamide plus bilateral orchiectomy
Number of subjects: 1387

Group type: COMPARATOR
Intervention: Placebo plus bilateral orchiectomy
Number of subjects: 1387
Study: 7824566

Group type: EXPERIMENTAL
Intervention: 0.30% menthol solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.03% menthol solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-min and 5-min inter-stimulus intervals
Number of subjects: 0
Study: 3401076

Group type: EXPERIMENTAL
Intervention: Cefamandole nafate
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Cefuroxime sodium
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Cefazolin sodium
Number of subjects: 903

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 903
Study: 31484786

Group type: EXPERIMENTAL
Intervention: Home NIV initiation
Number of subjects: 67

Group type: COMPARATOR
Intervention: In-hospital NIV initiation
Number of subjects: 67
Study: 29743026

Group type: EXPERIMENTAL
Intervention: Self-directed, integrated online and mobile phone behavioral intervention including a weight gain tracker, diet and physical activity goal-setting and self-monitoring tools.
Number of subjects: 1689

Group type: COMPARATOR
Intervention: Placebo control group with access to informational tools, event reminders, and a blogging feature.
Number of subjects: 1689
Study: 27650032

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement using DSA tumor blush
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intra-rater agreement using DSA tumor blush
Number of subjects: 46
Study: 26201312

Group type: EXPERIMENTAL
Intervention: VPZ 5 mg
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: VPZ 10 mg
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: VPZ 20 mg
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: VPZ 40 mg
Number of subjects: 732

Group type: COMPARATOR
Intervention: LPZ 30 mg
Number of subjects: 732
Study: 24213913

Group type: EXPERIMENTAL
Intervention: Guideline-adherent therapy
Number of subjects: 984

Group type: COMPARATOR
Intervention: Non-guideline-adherent therapy
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Guideline-recommended combination of amoxicillin-gentamicin
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Recommended regimens for patients with a catheter
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Guideline-adherent therapy for patients with a catheter
Number of subjects: 984
Study: 21521375

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1996
Study: 19043984

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with allergens absorbed on calcium phosphate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with allergens absorbed on aluminium hydroxide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 28
Study: 16575552

Group type: EXPERIMENTAL
Intervention: Ayahuasca (1.0 mg DMT/kg body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15000367

Group type: EXPERIMENTAL
Intervention: Resilient backpropagation neural network (BPNN) using neck movement variables as input
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 115
Study: 10743447

Group type: EXPERIMENTAL
Intervention: 1% lidocaine in sodium bicarbonate 0.1 mmol litre‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1% plain lidocaine
Number of subjects: 10
Study: 8694325

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 1 microgram/mL at thoracic level (Ts)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 1 microgram/mL at lumbar level (Ls)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 1 microgram/mL combined with bupivacaine 1 mg/mL at thoracic level (Tsb)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Epidural infusion (all groups)
Number of subjects: 37
Study: 9343570

Group type: EXPERIMENTAL
Intervention: Pixel counting method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tessellation method
Number of subjects: 100
Study: 3130255

Group type: EXPERIMENTAL
Intervention: Deoxycholate (DCA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholate (CDCA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholate (UDCA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hyodeoxycholate (HDCA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ursocholate (UCA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cholate (CA)
Number of subjects: 6
Study: 30347735

Group type: EXPERIMENTAL
Intervention: TRAIN (continued exercise for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: DETRAIN (discontinued exercise)
Number of subjects: 22
Study: 28482858

Group type: EXPERIMENTAL
Intervention: Dose reduction group (33% and 50% dose reduction of biologics)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (no dose reduction)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dose reduction group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 26185017

Group type: EXPERIMENTAL
Intervention: Use of diuretics
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Use of ACE-inhibitors
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Use of diuretics, insulin, and digitalis
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Combination of diuretic and ACE-inhibitor
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease
Number of subjects: 1213
Study: 23558157

Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Twice-daily darunavir/ritonavir (DRV/r) 600/100 mg
Number of subjects: 100
Study: 20854382

Group type: EXPERIMENTAL
Intervention: Lisinopril 20, 40 and 60 mg daily
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Normoalbuminuric group
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Microalbuminuric group
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Macroalbuminuric group
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: All diabetic groups (normo, micro, macroalbuminuric)
Number of subjects: 203
Study: 18173400

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using a bioresorbable PLA barrier device (Atrisorb) combined with autogenous bone grafting
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bone grafting solo (control)
Number of subjects: 40
Study: 16982943

Group type: EXPERIMENTAL
Intervention: Bosentan (62.5 mg for 1 day and 125 mg for the following 2 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15339556

Group type: EXPERIMENTAL
Intervention: Cinobufacini injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 10726719

Group type: EXPERIMENTAL
Intervention: Per 2/Ind 0.625 mg
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Per 4/Ind 1.25 mg
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Per 8/Ind 2.5 mg
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Per 0/Ind 1.25 mg
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Per 2/Ind 1.25 mg
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Other doses (0-4.6%)
Number of subjects: 438
Study: 8694206

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80
Study: 1485136

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (4 capsules/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 6585371

Group type: EXPERIMENTAL
Intervention: Tetracycline therapy for 2 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metronidazole therapy for 1 week
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined systemic antimicrobial therapy and mechanical plaque control
Number of subjects: 9
Study: 31237183

Group type: EXPERIMENTAL
Intervention: Tryptophan (1000 mg/day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (1000 mg/day)
Number of subjects: 98
Study: 29734387

Group type: EXPERIMENTAL
Intervention: Randomized T7 promoter variants
Number of subjects: 7847

Group type: EXPERIMENTAL
Intervention: In vitro transcription/translation system
Number of subjects: 7847
Study: 26960912

Group type: EXPERIMENTAL
Intervention: Educational intervention programme on the use of respiratory health status tools in primary care practices in Mallorca.
Number of subjects: 88194

Group type: COMPARATOR
Intervention: Control practices in Ibiza and Menorca (non-intervention group).
Number of subjects: 88194

Group type: EXPERIMENTAL
Intervention: Educational intervention programme on the use of respiratory health status tools.
Number of subjects: 88194
Study: 24885938

Group type: EXPERIMENTAL
Intervention: ART (hand instruments/high‐viscosity glass‐ionomer)
Number of subjects: 66

Group type: COMPARATOR
Intervention: CRT/clinic (rotary instrumentation/resin composite)
Number of subjects: 66

Group type: COMPARATOR
Intervention: CRT/GA (rotary instrumentation/resin composite under general anaesthesia)
Number of subjects: 66
Study: 22716975

Group type: COMPARATOR
Intervention: Zidovudine for 6 weeks (zidovudine-alone group)
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Zidovudine for 6 weeks plus three doses of nevirapine during the first 8 days of life (two-drug group)
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Zidovudine for 6 weeks plus nelfinavir and lamivudine for 2 weeks (three-drug group)
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Overall transmission rate
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Three-drug group
Number of subjects: 1684
Study: 19798489

Group type: EXPERIMENTAL
Intervention: Eye gaze cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arrow pointing distractors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (typical adults)
Number of subjects: 0
Study: 17683996

Group type: EXPERIMENTAL
Intervention: Intravenous clodronate (900 mg, n = 33)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 15621327

Group type: EXPERIMENTAL
Intervention: Multidimensional analysis technique
Number of subjects: 0
Study: 11880863

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg p.o., fast release form)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10430963

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical thrombolysis with urokinase
Number of subjects: 13

Group type: COMPARATOR
Intervention: Mechanical thrombolysis alone
Number of subjects: 13
Study: 7598063

Group type: EXPERIMENTAL
Intervention: Carbohydrate overfeeding (50% above energy requirements for 14 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fat overfeeding (50% above energy requirements for 14 days)
Number of subjects: 16
Study: 2135695

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7000598

Group type: EXPERIMENTAL
Intervention: Chlorpropamide treatment in insulin dependent diabetics
Number of subjects: 736

Group type: COMPARATOR
Intervention: Control group (no chlorpropamide treatment)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Non-insulin dependent diabetics
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Non-insulin dependent diabetics with family history
Number of subjects: 736
Study: 31968003

Group type: EXPERIMENTAL
Intervention: Pre-performance routine interventions
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cumulative PPR use
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Isolated PPR use
Number of subjects: 54